Syngene stock looks to stronger second half as revenue outlook holds

Published on 11/02/2026 at 01:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syngene stock is in focus after management retained its full-year outlook. The company expects a stronger second half on orders and customer deliveries.

Stronger second half in focus

Syngene expects second-half revenue to improve as its order book and customer deliveries support activity.
Management retained its full-year outlook for a single-digit revenue decline.
Biologics manufacturing and the Bayview facility remain central to the companys longer-term growth plans.

Syngene, INE398R01022, Illustration mit AI erstellt.

Syngene International expects a stronger second half of fiscal 2027, while retaining its full-year outlook for a single-digit revenue decline. Business Standard reported the outlook on Sunday, November 1, 2026, after the companys September-quarter results.

Revenue from operations rose 13 percent sequentially to INR 833 crore in Q2 FY27, but remained 9 percent below the year-earlier quarter. Profit after exceptional items reached INR 32 crore, compared with a loss of INR 9 crore in Q1 FY27. Management pointed to its order book, customer delivery commitments and planned Zoetis supplies as supports for the second half.

Zoetis gap still weighs

Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librella. The company said the absence of Librella revenue in the latest quarter was a major reason for the year-on-year decline. Supplies are expected in the fourth quarter, but management said the related biologics capacity will later need to be filled with multiple products and customers.

Operating EBITDA margin improved to 18 percent from 12 percent in the previous quarter, although it remained below 22 percent a year earlier. Management attributed much of the year-on-year pressure to hedge losses and said the adjusted margin would have been in the mid-20s. Syngene expects those losses to run their course over the next 18 to 24 months.

Share price and investor focus

Syngene stock traded at 403.00 INR on the National Stock Exchange of India at 3:29:48 p.m. IST on Friday, October 30, 2026. Investors can follow the real-time quote of Syngene stock. The key issue for investors is whether new customer wins can offset the temporary loss of Librella-related manufacturing revenue.

Business and competitive position

Syngene International is an India-based integrated research, development and manufacturing organization serving pharmaceutical, nutrition, animal-health, consumer-goods and specialty-chemical companies, according to its investor overview. Its services span early discovery through commercial supply, including small- and large-molecule work. It competes with larger global outsourcing groups such as Charles River Laboratories, IQVIA and Labcorp, while occupying a more specialized India-led position with growing US manufacturing capacity. The companys Bayview facility and Bengaluru operations are intended to strengthen that integrated delivery model.